# LUPIN LIMITED

## SAFETY DATA SHEET

### Section 1: Identification

**Material**
Mefenamic Acid Capsules USP, 250 mg

**Manufacturer**
Lupin Limited  
Goa 403 722  
INDIA

**Distributor**
Lupin Pharmaceuticals, Inc.  
111 South Calvert Street,  
Harborplace Tower, 21st Floor,  
Baltimore, Maryland 21202  
United States  
Tel. 001-410-576-2000  
Fax. 001-410-576-2221

### Section 2: Hazard(s) Identification

**Fire and Explosion**
Expected to be non-combustible.

**Health**
Mefenamic acid capsules are contraindicated in the following patients:

- Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to mefenamic acid or any components of the drug product.
- History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.
- In the setting of coronary artery bypass graft (CABG) surgery.

**Environment**
No information is available about the potential of this product to produce adverse environmental effects.

### Section 3: Composition/Information on Ingredients

**Ingredients**

<table>
<thead>
<tr>
<th>CAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>61-68-7</td>
</tr>
</tbody>
</table>

**Ingredients**

- Mefenamic Acid USP
### Section 4: First-Aid Measures

**Ingestion**  
If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.

**Inhalation**  
Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

**Skin Contact**  
Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

**Eye Contact**  
Flush eyes with plenty of water. Get medical attention.

#### NOTES TO HEALTH PROFESSIONALS

**Medical Treatment**  
Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient’s airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient’s vital signs, blood gases, serum electrolytes, etc.

**OVERDOSAGE**  
Symptoms following acute NSAID overdosages have been typically limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which have been generally reversible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure, respiratory depression and coma have occurred, but were rare.

Manage patients with symptomatic and supportive care following an NSAID overdose. There are no specific antidotes. Consider emesis and/or activated charcoal (60 to 100 grams in adults, 1 to 2 grams per kg of body weight in pediatric patients) and/or osmotic cathartic in symptomatic patients seen within four hours of ingestion or in patients with a large overdose (5 to 10 times the recommended dosage). Forced diuresis, alkalization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.

For additional information about overdosage treatment, contact a poison control center (1-800-222-1222).

### Section 5: Fire-Fighting Measures

**Fire and Explosion Hazards**  
Assume that this product is capable of sustaining combustion.

**Extinguishing Media**  
Water spray, carbon dioxide, dry chemical powder or appropriate foam.
### Special Firefighting Procedures

For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.

### Hazardous Combustion Products

Hazardous combustion or decomposition products are expected when the product is exposed to fire.

### Section 6: Accidental Release Measures

#### Section 6, Accidental release measures

**Personal Precautions**

Wear protective clothing and equipment consistent with the degree of hazard.

**Environmental Precautions**

For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

**Clean-up Methods**

Collect and place it in a suitable, properly labeled container for recovery or disposal.

### Section 7: Handling and Storage

#### Section 7, Handling and storage

**Handling**

No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.

**Storage**

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

### Section 8: Exposure Controls/ Personal Protection

#### Section 8, Exposure controls/personal protection

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

### Section 9: Physical and Chemical Properties

#### Section 9, Physical and chemical properties

**Physical Form**

Mefenamic acid capsules USP, 250 mg are available as size ‘1’ capsules having ivory cap and ivory body imprinted with “LU” on cap and “R31” on body in black ink, containing white to off white granular powder.

They are supplied as follows:
Section 10: Stability and Reactivity

Section 10, Stability and reactivity

Stable under recommended storage conditions.

Section 11: Toxicological Information

Section 11, Toxicological information

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Long-term studies in animals to evaluate the carcinogenic potential of mafenamic acid have not been conducted.

Mutagenesis

Studies to evaluate the mutagenic potential of mafenamic acid have not been completed.

Impairment of Fertility

Dietary administration of mafenamic acid to male rats 61 days- and to female rats 15 days- prior to mating through to Gestation Day (GD) 21 at a dose of 155 mg/kg/day (equivalent to the Maximum Recommended Human Dose [MRHD] of 1500 mg/day on a mg/m2 basis) resulted in decreased corpora lutea.

In another study rats administered upto 10-times a human dose of 250 mg showed decreased fertility.

Section 12: Ecological Information

Section 12: Ecological Information

No relevant studies identified.

Section 13: Disposal Considerations

Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.
Section 14: Transport Information

IATA/ICAO - Not Regulated
IATA Proper shipping Name : N/A
IATA UN/ID No : N/A
IATA Hazard Class : N/A
IATA Packaging Group : N/A
IATA Label : N/A

IMDG - Not Regulated
IMDG Proper shipping Name : N/A
IMDG UN/ID No : N/A
IMDG Hazard Class : N/A
IMDG Flash Point : N/A
IMDG Label : N/A

DOT - Not Regulated
DOT Proper shipping Name : N/A
DOT UN/ID No : N/A
DOT Hazard Class : N/A
DOT Flash Point : N/A
DOT Packing Group : N/A
DOT Label : N/A

Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.